

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
NRG GY018	A Phase III Randomized, Placebo-controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measureable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY006	Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer; Phase II; Radiation Therapy and Cisplatin Alone or in Combination with Intravenous <i>Triapine</i>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY005	PLATINUM-RESISTANT OR -REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY/Recurrent, Randomized Phase II/III Study of the Combination of <i>Cediranib</i> and <i>Olaparib</i> Compared to <i>Cediranib</i> or <i>Olaparib</i> alone, or Standard of Care Chemotherapy	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
CC008	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY009	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

STMW 2020.01	Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRP-αFc-CD40L) Administered Intravenously in Subjects with Ovarian Cancer	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
---------------------	--	-----------	--	---
